Cell Source, Inc. announced a private placement of 8% convertible notes for gross proceeds of $4,760,170 on March 22, 2024. The notes are convertible into series C convertible preferred stock at a conversion price of $7.50 per share. The company also issued investors warrants to purchase 4,321,926 shares at an exercise price of $1.25 per share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0008 USD | +300.00% | +300.00% | -99.83% |
22/03 | Cell Source, Inc. announced that it has received $4.76017 million in funding | CI |
2023 | Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-99.83% | 32.82K | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- CLCS Stock
- News Cell Source, Inc.
- Cell Source, Inc. announced that it has received $4.76017 million in funding